The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 receptor agonist retatrutide. https://joyceujed576540.blogsmine.com/39387808/glp-3-retatrutide-a-comparative-analysis